Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

Sara Bringhen, Mattia D’Agostino, Laura Paris, Stelvio Ballanti, Norbert Pescosta, Stefano Spada, Sara Pezzatti, Mariella Grasso, Delia Rota-Scalabrini, Luca De Rosa, Vincenzo Pavone, Giulia Gazzera, Sara Aquino, Marco Poggiu, Armando Santoro, Massimo Gentile, Luca Baldini, Maria Teresa Petrucci, Patrizia Tosi, Roberto Marasca, Claudia Cellini, Antonio Palumbo, Patrizia Falco, Roman Hájek, Mario Boccadoro, and Alessandra Larocca
Disclosures: Sara Bringhen has received honoraria from Bristol-Myers Squibb, Celgene, Amgen and Janssen; has served on the advisory boards for Amgen, Janssen, Celgene, and Karyopharm; and has undertaken consultancy for Takeda and Janssen. Stelvio Ballanti has received honoraria from Celgene, Janssen, Bristol-Myers Squibb, and Amgen. Sara Aquino has served on the advisory boards for Celgene and Amgen. Armando Santoro has served on the advisory boards for Bristol-Myers-Squibb, Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp & Dohme; has participated in the speaker’s bureaus for Takeda, Bristol-Myers-Squibb, Roche, AbbVie, Amgen, Celgene, Servier, Gilead, Astrazeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, and Merck Sharp & Dohme. Maria Teresa Petrucci has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Takeda, and served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. Roberto Marasca has received honoraria from Janssen, AbbVie, Gilead, Roche; has received a research grant from Janssen; has served on the advisory boards for Janssen, Shire, and Roche. Antonio Palumbo is currently a Takeda employee; data reported here have been generated during his previous Investigator role, and are not reflecting any Takeda’s position. He has ownership interests (including stock options) in Takeda. All the following Prof. Palumbo’s conflicts of interest refer to a period of more than two years ago: he had received honoraria from and undertook consultancy for Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, and Merck; he had received research funding from Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, Merck, and Binding Site; he had served on the Speakers’ Bureau for Bristol-Myers Squibb. Roman Hájek has received honoraria from Amgen, Bristol-Myers Squibb, Takeda, Celgene, Janssen; has received research funding from Takeda, Novartis, Amgen, Janssen; had a consultant or advisory relationship with Amgen, Takeda, Bristol-Myers Squibb, Celgene, and Janssen. Mario Boccadoro has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, AbbVie, and Bristol-Myers Squibb; has received research funding from Celgene, Janssen, Amgen, Bristol-Myers Squibb, Mundipharma, Novartis, and Sanofi. Alessandra Larocca has received honoraria from Amgen, Bristol-Myers Squibb, Celgene and Janssen-Cilag; has served on the advisory boards for Bristol-Myers Squibb, Celgene, Janssen-Cilag, and Takeda. The remaining authors declare no competing financial interests.

Contributions: Substantial contributions to the conception or design: SB, AP, MB, and AL. Acquisition, analysis, or interpretation of data: all authors. First draft: SB and MD Statistical analysis: SS. Critical revision for important intellectual content: all authors. Final approval of the version to be published: all authors. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: all authors. Supervision: SB, MB, and AL.